Year: 2021
Type: article
Abstract: In December 2020, Israel initiated a successful national vaccination program with the Pfizer-BioNTech mRNA SARS-CoV-2 vaccine.Shavit et al 1 conducted an 8-week prospective cohort study in which they risk stratified potentially allergic patients into low-risk and high-risk groups prior to vaccination.Patients considered to be at higher risk (or highly allergic) were monitored at a single specialty center for 2 hours after vaccination, while those considered to be at low risk of allergic reactions would undergo the regular protocol of 30-minute monitoring after vaccination in the routine setting.Interestingly, the low-risk allergy groups included many of those overrepresented in anaphylaxis reports in the Centers for Disease Control and Prevention's Vaccine Adverse Event Reporting System (VAERS) 2 : those who had chronic urticaria; sensitivity to foods, venoms, or aeroallergens; or nonanaphylactic reactions to drugs or contrast media.Patients at high risk for allergic reactions were those with a history of mast cell disorders, multiple drug allergies, multiple allergies, or a history of anaphylaxis to a drug or vaccine as well as those for whom their primary physician, allergist, or immunization team did not feel comfortable vaccinating in the routine setting.
Source: JAMA Network Open
Author: Elizabeth J. Phillips
Institution: Vanderbilt University Medical Center
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W3198857197